Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Here's What Else Gilead Sciences Gets by Buying Kite Pharma

TheMotleyFool

0 0

Here's What Else Gilead Sciences Gets by Buying Kite Pharma

Gilead Sciences' (NASDAQ: GILD) planned $11.9 billion acquisition of Kite Pharma (NASDAQ: KITE) nets it axi-cel, a CAR-T therapy that's already under FDA review. However, axi-cel isn't the only intriguing therapy in development at Kite Pharma. Gilead Sciences also gets its hand on next-generation TCR-targeting drugs that could someday change how doctors treat patients with solid tumor cancers.

Gilead Sciences has been planning for years to make a big splash in oncology, and on Monday, it announced that it is acquiring Kite Pharma for nearly $12 billion in cash.

Image source: Getty Images.

Source: Fool.com